Physician profile
Sara Johnson
NPI 1043206964
$10,554.31
in general payments reported to CMS, 2019-2025
33 companies · $29.30 in 2025
The $29.30 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,423 · 2020: $748 · 2021: $2,103 · 2022: $2,705 · 2023: $1,547 · 2025: $29.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,475.35 | 2019-2023 | Tremfya, Stelara, Simponi |
| Amgen INC. | $1,400.53 | 2019-2023 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $1,117.44 | 2019-2023 | |
| Pfizer INC. | $1,021.14 | 2019-2023 | |
| Ucb, INC. | $627.85 | 2019-2023 | Cimzia |
| Lilly USA, LLC | $584.31 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $529.54 | 2019-2023 | |
| Horizon Therapeutics Plc | $459.00 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $377.01 | 2019-2023 | Actemra, Rituxan |
| Astrazeneca Pharmaceuticals LP | $348.01 | 2021-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $314.59 | 2019-2023 | Benlysta |
| Radius Health, INC. | $306.22 | 2019-2023 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $268.16 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $254.41 | 2021-2023 | Lupkynis |
| Mallinckrodt Enterprises LLC | $234.06 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $177.04 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.67 | 2021-2023 | Ofev |
| Sobi, INC | $105.54 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $105.34 | 2022-2023 | Purified Cortrophin Gel |
| Celgene Corporation | $89.49 | 2019 | |
| Mallinckrodt Hospital Products INC. | $82.72 | 2020-2022 | |
| Antares Pharma, INC. | $62.85 | 2019 | |
| Ferring Pharmaceuticals INC. | $61.17 | 2019-2023 | Euflexxa |
| Kiniksa Pharmaceuticals, LTD. | $56.96 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $53.04 | 2022-2023 | Orencia |
| Merck Sharp & Dohme LLC | $51.44 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $47.28 | 2019-2021 | |
| Fidia Pharma USA INC. | $46.86 | 2019-2022 | |
| Genzyme Corporation | $33.63 | 2023 | |
| Alexion Pharmaceuticals, INC. | $32.86 | 2021 | |
| Incyte Corporation | $29.30 | 2025 | Opzelura |
| Depuy Synthes Sales INC. | $24.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.